Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan alternative dosing in triple-negative breast cancer
NCT06926920Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 3 years and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06926920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926920.